Bufadienolides Overcome TRAIL Resistance in Breast Cancer Cells via JAK-STAT Pathway

Lia Hafiyani, Satoru Yokoyama, Sherif Abdelhamed, Yoshihiro Hayakawa and Ikuo Saiki*
Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Toyama, Japan

Abstract

Aim and objective: Although the clinical significance of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been elucidated, primary or acquired resistance to TRAIL limits its efficacy in cancer patients. This study aimed to investigate bufadienolides as promising candidates to combine with TRAIL and to determine the pathway involved in overcoming TRAIL resistance in breast cancer cells.

Methods: The effects of bufadienolides, cinobufagin and cinobufotalin, in combination with TRAIL were examined in TRAIL-sensitive and TRAIL-resistant breast cancer cells, MDA-MB-231 and MDA-MB-468 cells, respectively. Cell viability was determined using cell counting and viability assays. Apoptotic cell death was detected by annexin-V/7-AAD staining. Silencing of MCL-1 expression was established using MCL-1 siRNA and protein expression was assessed by Western blot analysis. STAT3 localization was determined using immunofluorescence staining.

Results: The combination of bufadienolides with TRAIL significantly reduced cell viability in both TRAIL-sensitive and TRAIL-resistant breast cancer cells in vitro. Bufadienolides overcame TRAIL resistance by downregulating MCL-1, an anti-apoptotic protein, through the JAK-STAT pathway. The combination of TRAIL with knock down of MCL-1 or JAK-STAT inhibitor, JSI-124, could synergistically induce apoptosis similar to bufadienolides.

Conclusion: Bufadienolides enhance TRAIL-induced apoptosis in breast cancer cells through Mcl-1 downregulation via JAK-STAT pathway. Targeting MCL-1 or JAK2 could be one of the strategies to overcome breast cancer cell resistance to TRAIL. Bufadienolides, through JAK2/STAT3/MCL-1 inhibition, could be considered as promising cancer therapy agents in combination with TRAIL.

Keywords: Bufadienolides; MCL-1; Breast cancer; JAK-STAT pathway

Introduction

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women in both economically developed and developing countries, accounting for 23% of total new cancer cases and 14% of total cancer deaths in 2008 [1]. According to the molecular markers to determine prognosis and treatment, breast cancers can be classified into estrogen receptor (ER)-positive tumors, progesterone receptor (PR)-positive tumors, overexpress one of the members of the epidermal-growth-factor receptor family (HER2/Neu)-positive tumors, or none of these; known as triple-negative breast cancer (TNBC) [2]. Due to its lack of three receptors, TNBC therapy is a difficult clinical challenge because of its unresponsiveness to endocrine therapy or other available targeted therapy.

While endocrine therapy cannot help in the management of TNBC, a promising therapy for various types of cancers including TNBC is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) because of its high selectivity for various carcinomas over normal cells [3]. TRAIL has been shown to induce apoptosis via both extrinsic (non-mitochondrial) and intrinsic (mitochondrial) pathways [4-6]. Even though the clinical significance of TRAIL has been investigated [7], primary or acquired resistance to TRAIL limits its clinical efficacy in cancer patients [8,9]. Several molecules are involved in TRAIL resistance, including the involvement of anti-apoptotic mechanisms (BCL-2, MCL-1, BCL-XL, etc.), defects in death receptor signaling (death receptor 4 and death receptor 5), and overexpression of Six1 [8-12]. However, even though the antitumor effect of TRAIL as a single agent is limited, TRAIL exerts marked antitumor activity upon combination with various cytotoxic drugs [6,10].

It has been reported that chemical compounds from natural products could overcome TRAIL resistance, such as chrysin, curcumin, and wogonin [13-18]. Among these natural products, we focused on two bufadienolides, cinobufagin and cinobufotalin, which are known as cardiotonic steroids, because their antitumor activities as single agents in a wide type of tumors have been previously shown [19-21]. Bufadienolides are the major constituents of cinobufacini extracted from the skin and parotid venom glands of the giant toad Bufo bufo gargarizans Cantor, which has been widely used for thousands of years in China as a cardiotonic, antimicrobial, local anesthetic, and anti-neoplastic agent in clinical practice [21].

In this study, we demonstrate bufadienolides as promising candidates to TRAIL-based combination therapy, and investigate the molecular pathway involved in its effect to overcome TRAIL resistance in MDA-MB-468 breast cancer cells.

Materials and Methods

Drugs and reagents

Cinobufagin and cinobufotalin were purchased from Wako Pure

Received February 04, 2014; Accepted February 28, 2014; Published March 03, 2014


Copyright: © 2014 Hafiyani L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Chemical Industries, Ltd. (Osaka, Japan). Recombinant human TRAIL was purchased from PeproTech (PeproTech, London, UK).

Cell culture

MDA-MB-231 and MDA-MB-468 (ATCC, Rockville, MD, USA) were cultured in Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 10 µg/ml streptomycin. Cells were maintained at 37°C in a humidified atmosphere of 5% CO2/95% air.

Count and cell viability assay

Viability of the cells following treatment was determined using the MUSE Count and Viability Kit (Merck KGaA, Darmstadt, Germany) according to the manufacturer’s instructions. Briefly, cinobufagin- or cinobufotalin-containing medium was added at a final concentration of 10, 25, and 50 µM and, after 30 min, TRAIL was added. After 24 h further incubation, all cells were collected and diluted with phosphate buffered saline (PBS) to a concentration of 2 × 10^6 cells/ml. 50 µl of cell suspension was then added into 450 µl MUSE Count and Viability reagent (10x dilution), incubated for 5 min at room temperature, and analyzed using the MUSE Cell Analyzer. Relative cell viability and synergistic effects were determined as previously described [22,23].

Annexin V & dead cell assay

Apoptotic cell number was determined using the MUSE Annexin V & Dead Cell Kit (Merck KGaA) according to the manufacturer’s instructions. Briefly, after cells were incubated for 24 h, cinobufagin- or cinobufotalin-containing medium was added, cells were incubated for 30 min, and then stimulated with TRAIL. After 12 h further incubation, all cells were collected and diluted with PBS containing 1% bovine serum albumin (BSA) as a dilution buffer to a concentration of 5 × 10^6 cells/ml. 100 µl of cell suspension was then added to 100 µl MUSE Annexin V & dead cell reagent (2 × dilution), incubated for 20 min at room temperature, and analyzed using the MUSE Cell Analyzer.

Western blot analysis

After treatment, whole cell lysates, cytoplasmic extracts, and nuclear extracts were collected as described previously [23]. Equal amounts of protein were resolved by electrophoresis on acrylamide gels. Primary antibodies specific to caspase-3, poly (ADP-ribose) polymerase (PARP), XIAP, MCL-1, BCL-XL, BCL-2, BAX, FLIP, TRAF2, TRAF5, STAT3 and the phosphorylated form of STAT3 (Tyr705 and Ser727), AKT (Ser473), ERK1/2 (Thr202/Tyr204), p65 NF-kB (Ser536) were purchased from Cell Signaling Technology (MA, USA). Primary antibodies specific to β-actin, AKT, ERK1/2, and p65 NF-kB were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Transfection of small interfering RNAs

Silencing of MCL-1 expression in MDA-MB-468 cells was performed as described previously [13]. Human MCL-1 Stealth RNAi siRNA (HSS181042) was purchased from Invitrogen, (Carlsbad, CA, USA). Firefly luciferase siRNA was obtained from Hokkaido System Science Co. Ltd. (Sapporo, Japan) and used as control siRNA. MDA-MB-468 cells were transfected with each siRNA at a final concentration of 20 nM, using Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA).

Immunofluorescence staining

After 12 h bufadienolide treatment, cells were washed with warm PBS, fixed with 4% paraformaldehyde for 10 min at room temperature, permeabilized with 0.1% Triton-X/PBS for 10 min at RT and blocked with 1% BSA/0.1% Triton-X solution for 1 hr at RT. For the detection of STAT3, cells were incubated with the primary antibody (x100) for 12 h at 4°C. After washing, cells were treated with secondary antibody (x30) using Rhodamine-conjugated swine anti-rabbit IgG (DakoCytomation, Glostrup, Denmark) for 1 h at RT. Finally, cells were mounted using VECTASHIELD mounting medium containing 4/6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA). Confocal fluorescence images were observed by LSM700 microscopy and ZEN software (Carl Zeiss, Oberkochen, Germany).

Statistical analysis

The results are expressed as the mean ± standard deviation. Statistical significance (p<0.05) was evaluated by either Student’s two-tailed t-test or one-way ANOVA followed by the Bonferroni post hoc test, comparing the results to the control.

Results

Combination with bufadienolides enhances TRAIL-induced apoptosis in triple-negative breast cancer cells

To evaluate the cytotoxicity of bufadienolides, cinobufagin and cinobufotalin (Figure 1a), and their combination with TRAIL in TNBC cells, we chose TRAIL-sensitive or -resistant TNBC cells, MDA-MB-231 or MDA-MB-468, respectively [22]. Even though bufadienolides have been shown to be anti-tumor agents [19-21], these compounds showed limited cytotoxicity in both TNBC cell lines (Figure 1b). Interestingly, both bufadienolides could significantly increase TRAIL-induced cytotoxicity in TNBC cells, even in TRAIL-resistant cells, MDA-MB-468 cells, compared to single therapy with TRAIL or bufadienolides alone.

We next examined whether bufadienolides overcome TRAIL resistance in TRAIL-resistant cells through apoptosis, because only the combination of bufadienolides with TRAIL could show cytotoxicity even in MDA-MB-468 cells, without any cytotoxicity by either bufadienolides or TRAIL alone. Annexin-V-positive cells were increased in TRAIL/ bufadienolide-treated cells compared with non-treated, TRAIL-treated, or bufadienolide-treated cells (Figure 1c). In addition, the cleavage of pro-caspase-3, and poly (ADP-ribose) polymerase (PARP) protein were detected as hallmarks of apoptosis only in TRAIL/bufadienolide-treated cells (Figure 1d). These data suggest that bufadienolides could overcome TRAIL resistance in TRAIL-resistant TNBC cells.

Bufadienolides suppress MCL-1 expression

To identify the mechanisms by which bufadienolides overcome TRAIL resistance, we further examined several proteins related to
either intrinsic (BCL-2, BCL-XL, MCL-1, BAX) or extrinsic (TRAF2, TRAF5, XIAP, FLIP) pathways of TRAIL in MDA-MB-468 cells [4-6]. Both cinobufagin and cinobufotalin could selectively suppress MCL-1 expression with either bufadienolide alone or in combination with TRAIL (Figure 2a). We also confirmed the time- and dose-dependent MCL-1 suppression in concert with the induction of apoptotic markers (Figure 2b), suggesting that MCL-1 could be involved in overcoming TRAIL resistance.

Silencing MCL-1 expression is sufficient to overcome TRAIL resistance in MDA-MB-468 cells

To investigate its role in overcoming TRAIL resistance, MCL-1 was knocked down in MDA-MB-468 cells using siRNA against MCL-1 (siMCL-1). The cleavage of caspase-3 and PARP could be detected only in siMCL-1-transfected cells with TRAIL (Figure 3a). Consistently, we could also detect apoptosis by using annexin V staining in siMCL-1-transfected cells treated with TRAIL (Figure 3b). Taken together, MCL-1 downregulation is sufficient to overcome TRAIL resistance in MDA-MB-468, and to induce apoptosis with TRAIL.
Inhibition of STAT3 phosphorylation and nuclear translocation mediate MCL-1 downregulation by bufadienolides in MDA-MB-468 cells

We further examined the effects of bufadienolides on several MCL-1 upstream proteins related to AKT, ERK, NF-κB, and STAT pathways [24]. Amongst these proteins, bufadienolides markedly suppressed constitutive STAT3 tyrosine phosphorylation (Tyr705), which is necessary for STAT3 translocation to the nucleus and its transcriptional activity in the targeted genes, including MCL-1 [25,26]. The downregulation of pSTAT3 Tyr705 by bufadienolides was highly correlated to the decrease of MCL-1 protein in a dose- and time-dependent manner (Figures 4a and 4b). The phosphorylation at Ser727 of STAT3 could not be inhibited by bufadienolides, indicating that its inhibitory activity is specific to tyrosine kinases but not to serine/threonine kinases. To check the STAT3 nuclear localization, we performed immunofluorescence staining and Western blot analysis (Figures 4c and 4d). After bufadienolide treatments, STAT3 showed a ring-like appearance, indicating its localization in cytoplasm, while it was distributed evenly and diffusively both in the nucleus and cytoplasm of non-treated cells (Figure 4c). Similar to immunofluorescent staining, we could detect the suppression of nuclear STAT3 by Western blot analysis using antibodies against the indicated proteins.
JAK2 inhibition is sufficient to show synergistic effects of bufadienolides with TRAIL in MDA-MB-468 cells

To identify the upstream target of bufadienolides, we focused on the two major tyrosine kinases involved in STAT3 phosphorylation in breast cancer cells: JAK2 and Src [25-29]. Both the protein expression and phosphorylation of JAK2 were decreased by bufadienolides, while phosphorylation of Src remained unaffected (Figure 5a), suggesting that the downregulation of STAT3 phosphorylation by bufadienolides might be caused by suppression of JAK2 protein expression in MDA-MB-468 cells. Finally, to confirm the significance of the JAK-STAT pathway in overcoming TRAIL resistance, we inhibited the JAK-STAT pathway by using 1 µM JSI-124 (Cucurbitacin I) [30]. Strikingly, the combination of JSI-124 and TRAIL was sufficient to sensitize cancer cells to TRAIL, even though either JSI-124 or TRAIL alone could not induce apoptosis (Figure 5b). These results suggest that overcoming TRAIL resistance by bufadienolides could be mediated through inhibition of the JAK2-STAT3 pathway.

Discussion

Our study showed that the combination of TRAIL and bufadienolides synergistically induced apoptosis in TRAIL-sensitive and even in TRAIL-resistant TNBC cells in vitro. Furthermore, bufadienolides enhanced apoptosis by decreasing MCL-1 expression, which is mediated through JAK2/STAT3 Tyr705 phosphorylation pathways.

Although TRAIL-based therapies, including anti-death receptor 5 agonistic antibody, have provided a significant clinical benefit in some cancer patients in clinical trials [7], the acquisition of drug resistance is known to limit the efficacy of TRAIL-based therapy [8,9]. Moreover, there are some inherently TRAIL-resistant breast cancers, and TRAIL resistance can also be acquired by cells that were originally TRAIL sensitive [10]. There is some evidence that BCL-2 family members containing MCL-1 are involved in TRAIL-resistance in cancer cells by enhancing the intrinsic pathways of TRAIL [31-35]. Consistently, we showed that knocking down MCL-1 is sufficient to overcome TRAIL resistance in MDA-MB-468 cells (Figure 3), regardless of a lack of change in the caspase-8 or other extrinsic and intrinsic pathway-related proteins (Figure 2). Similar to MDA-MB-468 cells, MCL-1 downregulation is sufficient to overcome TRAIL resistance in A549 human lung adenocarcinoma cells [13]. Further investigation is still needed to confirm the significance of MCL-1 in other types of TRAIL-resistant cancers and its role in determining TRAIL-resistant cell lines compared to TRAIL-sensitive cells. However, our results and those reported previously suggest that MCL-1 is one of the most important molecules for TRAIL-based therapy and could be a good therapeutic target to overcome TRAIL resistance.

Although an MCL-1 inhibitor is a good candidate for combination therapy with TRAIL, it has been difficult to target only MCL-1 itself by BCL-2 family inhibitors. In addition to MCL-1, we identified the significance of the JAK2-STAT3 pathway in overcoming TRAIL resistance by bufadienolides (Figure 4 and 5). Clinically, persistent activation of STAT3 has been shown in a variety of human cancers, including pancreatic, prostate, ovarian, hepatic, and breast carcinomas, as well as in hematopoietic tumors, including lymphomas and leukemia [36-42], and also has been correlated with a poor prognosis [36,43]. In addition to constitutive active STAT3, IL-6 production in breast cancer cells plays a critical role in activating the JAK-STAT pathway and is widely known to be highly correlated with tumor cell proliferation, advanced stage breast cancers, and poor prognosis [44].
Given that human breast cancers produce more IL-6, which activates the JAK/STAT pathway, that matched healthy breast tissue, inhibition of the JAK/STAT pathway could be a promising target for breast cancer therapy.

We determined that bufadienolides suppressed MCL-1 expression via the JAK-STAT pathway; however our study could not exclude the possibility that other pathways were also involved in its effect on TRAIL sensitization. Previously, Bufadienolides have been shown to be cardiac glycosides, potent Na+ K+ -ATPase inhibitors. Ouabain, also a cardiac glycoside, could suppress MCL-1 through ROS-mediated proteasomal degradation [45]. Another cardiac glycoside, thevefolin, overcomes TRAIL-resistance through enhancing the expression of TRAIL receptors in gastric cancer [46]. In addition to their role in TRAIL-induced apoptosis, inhibition of Na+ K+ -ATPase by cardiac glycosides is important for overcoming multi-drug resistance and promoting anoikis [47,48], suggesting another possible role for cardiac glycosides in cancer therapy.

Taken together, pending further in vivo and clinical experiments to determine safe and optimal doses, bufadienolides or JAK inhibitors can be considered not only as adjuvants with TRAIL but also as single agents for triple-negative breast cancer therapy.

Acknowledgement

We thank all members of the Saiki laboratory for discussions and suggestions. This study was supported in part by a Grant-in-Aid for Young Scientists (B) (No.24700971) (S.Y.), by Grant-in-aid for Challenging Exploratory Research 24659348 (I.S.) from the Ministry of Education, Culture, Sports, Science, and Technology (Japan), by The YASUDA Medical Foundation (S.Y.), by a Grant-in-Aid for the Cooperative Research Project (I.S.) from Joint Usage/Research Center (Joint Usage/Research Center for Science-Based Natural Medicine), Institute of Natural Medicine, University of Toyama in 2013.

References